Genscript Biotech Corporation (G51) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genscript Biotech Corporation (G51) has a cash flow conversion efficiency ratio of -0.045x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-93.58 Million ≈ $-109.41 Million USD) by net assets (€2.09 Billion ≈ $2.44 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genscript Biotech Corporation - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Genscript Biotech Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Genscript Biotech Corporation carry for a breakdown of total debt and financial obligations.
Genscript Biotech Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genscript Biotech Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marex Group plc Ordinary Shares
NASDAQ:MRX
|
0.784x |
|
Metro Brands Limited
NSE:METROBRAND
|
0.076x |
|
ZF Commercial Vehicle Control Systems India Limited
NSE:ZFCVINDIA
|
0.015x |
|
Valeo SA
PA:FR
|
0.246x |
|
Standex International Corporation
NYSE:SXI
|
0.028x |
|
Chengdu Xingrong Investment Co Ltd
SHE:000598
|
0.070x |
|
AIR CHINA LTD H ADR/20
F:AD2B
|
N/A |
|
Virbac SA
PA:VIRP
|
0.023x |
Annual Cash Flow Conversion Efficiency for Genscript Biotech Corporation (2016–2024)
The table below shows the annual cash flow conversion efficiency of Genscript Biotech Corporation from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Genscript Biotech Corporation worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €4.32 Billion ≈ $5.05 Billion |
€75.65 Million ≈ $88.44 Million |
0.017x | +112.47% |
| 2023-12-31 | €2.04 Billion ≈ $2.39 Billion |
€-286.91 Million ≈ $-335.43 Million |
-0.140x | -58.98% |
| 2022-12-31 | €1.36 Billion ≈ $1.59 Billion |
€-120.29 Million ≈ $-140.63 Million |
-0.088x | +29.47% |
| 2021-12-31 | €1.09 Billion ≈ $1.28 Billion |
€-136.79 Million ≈ $-159.92 Million |
-0.125x | +32.44% |
| 2020-12-31 | €815.59 Million ≈ $953.51 Million |
€-151.09 Million ≈ $-176.64 Million |
-0.185x | -130.25% |
| 2019-12-31 | €372.30 Million ≈ $435.26 Million |
€-29.95 Million ≈ $-35.02 Million |
-0.080x | -112.90% |
| 2018-12-31 | €493.30 Million ≈ $576.72 Million |
€307.66 Million ≈ $359.69 Million |
0.624x | +566.40% |
| 2017-12-31 | €228.32 Million ≈ $266.93 Million |
€21.37 Million ≈ $24.98 Million |
0.094x | -48.24% |
| 2016-12-31 | €184.02 Million ≈ $215.14 Million |
€33.27 Million ≈ $38.90 Million |
0.181x | -- |
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Lif… Read more